Annual jab for HIV protection passes trial hurdle
An annual injection designed by California’s Gilead Sciences to guard against HIV has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. For the trial, 40 people without HIV were injected into the muscle with lenacapavir, with no major side effects or safety concerns. And after 56 weeks, the medicine was still detectable in their bodies. If future trials go well, it could become the longest-acting form of HIV prevention available.









